Avenue Therapeutics, Inc.

NasdaqCM:ATXI Stock Report

Market Cap: US$3.4m

Avenue Therapeutics Future Growth

Future criteria checks 0/6

Avenue Therapeutics is forecast to grow earnings and revenue by 24.3% and 100.3% per annum respectively while EPS is expected to grow by 60.6% per annum.

Key information

24.3%

Earnings growth rate

60.6%

EPS growth rate

Pharmaceuticals earnings growth23.9%
Revenue growth rate100.3%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Nov 2024

Recent future growth updates

Recent updates

Avenue Therapeutics shares slide on pricing $12M securities offering

Oct 07

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Sep 22

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

Jun 14

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Mar 19
We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

How Many Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares Do Institutions Own?

Jan 23
How Many Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares Do Institutions Own?

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Dec 19
We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics issues regulatory update for IV tramadol

Dec 17

Earnings and Revenue Growth Forecasts

NasdaqCM:ATXI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-17N/AN/A1
12/31/2025N/A-14N/AN/A1
12/31/2024N/A-12N/AN/A1
9/30/2024N/A-18-11-11N/A
6/30/2024N/A-15-10-9N/A
3/31/2024N/A-11-14-11N/A
12/31/2023N/A-10-12-9N/A
9/30/2023N/A-10-14-11N/A
6/30/2023N/A-12-13-11N/A
3/31/2023N/A-8-7-7N/A
12/31/2022N/A-4-8-8N/A
9/30/2022N/A-5-5-5N/A
6/30/2022N/A-5-5-5N/A
3/31/2022N/A-6-4-4N/A
12/31/2021N/A-4-4-4N/A
9/30/2021N/A-4-4-4N/A
6/30/2021N/A-4-4-4N/A
3/31/2021N/A-5-5-5N/A
12/31/2020N/A-5-5-5N/A
9/30/2020N/A-10-8-8N/A
6/30/2020N/A-11-9-9N/A
3/31/2020N/A-16-22-22N/A
12/31/2019N/A-26-26-26N/A
9/30/2019N/A-24-23-23N/A
6/30/2019N/A-25-25-25N/A
3/31/2019N/A-22-17-17N/A
12/31/2018N/A-22-18-18N/A
9/30/2018N/A-24-21-21N/A
6/30/2018N/A-24N/A-19N/A
3/31/2018N/A-22N/A-14N/A
12/31/2017N/A-12N/A-7N/A
9/30/2017N/A-7N/A-3N/A
6/30/2017N/A-4N/A-1N/A
3/31/2017N/A-3N/A-1N/A
12/31/2016N/A-3N/A-2N/A
9/30/2016N/A-4N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATXI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ATXI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ATXI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ATXI is forecast to have no revenue next year.

High Growth Revenue: ATXI is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ATXI's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 20:30
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Avenue Therapeutics, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffB. Riley Wealth
Antonio ArceH.C. Wainwright & Co.
Jason McCarthyMaxim Group